Clinical trials: Decompensated Cirrhosis
Cirrhosis, Liver
Microbiome Translocation in Different Circulatory Compartments in Decompensated Cirrhosis
Acquired dysfunctional immunity in cirrhosis predisposes patients to frequent bacterial infections contributing to disease progression and may lead to the development of acute-on-chronic liver failure (ACLF).
- Trial name
- NCT04195724
- Testing
- mNGS for pathogen detection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Decompensated Cirrhosis
HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial
Three sequential dose cohorts are predefined for single administration: Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), and Cohort 3 (4.0 × 10⁶ cells/kg).
- Trial name
- HCL001 (NCT07488546)
- Testing
- Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), Cohort 3 (4.0 × 10⁶ cells/kg)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Huicun Medical Technology Co., Ltd.
Cirrhosis, Cirrhosis Advanced
Lung Point of Care Ultrasound to Guide Albumin Administration in Cirrhosis
To guide the administration of intravenous albumin by lung ultrasound in decompensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis Advanced, Acute Kidney Injury, Ascites
- Trial name
- POCUS (NCT07072572)
- Testing
- Lower albumin dosage
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Centro Medico Issemym
Decompensated Cirrhosis
Management of Decompensated HCV Cirrhotic Patients
-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV) remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with complications as worsening decompensation.
- Trial name
- NCT03547895
- Testing
- Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol), vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Hepatic Encephalopathy, Decompensated Cirrhosis
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Rationale Patients who recover from an episode of overt HE(OHE) are at risk of recurrent episodes of HE and persistent minimal hepatic encephalopathy, impacting their daily functioning and mental health.
- Conditions
- Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy
- Trial name
- HERB (NCT06538077)
- Testing
- Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose
- Where
- India
- Volunteers
- 336 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Decompensated Liver Cirrhosis
A Study of ADR-001 in Patients With Liver Cirrhosis
This is a first-in-human Phase1/2 study of ADR-001, adipose-derived mesenchymal stem cells (AD-MSCs). The safety and preliminary efficacy are evaluated in Phase 1 in patients with liver cirrhosis caused by Hepatitis C or…
- Trial name
- NCT03254758
- Testing
- Mesenchymal stem cell
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Paracentesis-Induced Circulatory Dysfunction
Low-dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis (LVP) in Decompensated Cirrhosis Liver.
Abstract for thesis protocol. Background: Paracentesis induced circulatory dysfunction (PICD) is a common complication of large volume paracentesis in cirrhotic patients, which can lead to renal impairment, hyponatremia, and…
- Trial name
- PICD LVP (NCT06892535)
- Testing
- Albumin infusion, 2g/L of ascitic fluid aspiration.
- Where
- Bangladesh
- Volunteers
- 52 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard…
- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Trial name
- NCT06987968
- Testing
- VS-01 on top of SOC (Active Treatment Group), SOC
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Genfit
Liver Cirrhosis, Alcoholic
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis.
- Trial name
- NCT06057870
- Testing
- Application on Apple watch
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Liver Cirrhosis, Diabetes Mellitus
Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes
The liver plays a crucial role in physiological glycemic control through its involvement in several glucose metabolism processes, including glycogenogenesis and glycogenolysis.
- Trial name
- NCT02325622
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Decompensated Cirrhosis, Acute-On-Chronic Liver Failure
Albumin Infusion in Inpatients With Decompensated Cirrhosis
Albumin infusion in patients with hospitalized decompensated, even in short-term period use, could improve survival through the reduction of systemic inflammation, which is the main driver of acute-on-chronic liver failure in…
- Trial name
- NCT05719051
- Testing
- Albumin infusion
- Where
- China
- Volunteers
- 564 people
- Sponsor
- Ruijin Hospital
Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of…
- Conditions
- Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
- Trial name
- LEAD-2 (NCT07087041)
- Where
- 28 sites in China
- Volunteers
- 735 people
- Sponsor
- Beijing Friendship Hospital
Decompensated Cirrhosis, Bleeding Varices
Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
The purpose of this study is to determine whether early use of transjugular intrahepatic portosystemic shunt (TIPS) with Polytetrafluoroethylene (PTFE) covered stents is able to prolong the survival in patients with advanced…
- Trial name
- NCT01370161
- Testing
- TIPS treatment, Medical treatment
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Air Force Military Medical University, China
HCV Related Cirrhosis
To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis
In this prospective randomized trial, A Minimum of 300 consecutive patients of decompensated HCV (Hepatitis C Virus) related cirrhosis, presenting to the Institute of Liver and Biliary Sciences hospital will be included and those…
- Trial name
- NCT02464631
- Testing
- Sofosbuvir + Ribavirin 1, Sofosbuvir + Ribavirin 2, Sofosbuvir + Ribavirin 3
- Where
- India
- Volunteers
- 62 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis.
- Trial name
- NCT06134544
- Testing
- Isomaltooligosaccharides (IMO)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Decompensated Cirrhosis, Portal Hypertension
TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding
The purpose of this study is to determine whether transjugular intrahepatic portosystemic shunt (TIPS) with 10-mm covered stent is associated with lower shunt dysfunction in comparing TIPS with 8-mm covered stent in cirrhotic…
- Conditions
- Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices
- Trial name
- T8/10SVB (NCT01410591)
- Testing
- 8-mm covered stent group, 10-mm covered stent group
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Air Force Military Medical University, China
Liver Cirrhosis
Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients
Liver cirrhosis (LC) is the final outcome for chronic liver diseases. The liver transplantation is the sole effective therapy available to these patients.
- Trial name
- NCT01120925
- Testing
- MNC, CD133, Control
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Royan Institute
NASH Related Decompensated Cirrhosis
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
The study will be conducted in the Department of Hepatology, Institute of Liver \& Biliary Sciences, New Delhi. As a part of this study history will be taken and clinical examination will be done.
- Trial name
- NCT02868164
- Testing
- Fecal Microbiota Transplantation, Standard Treatment, Weight Reduction
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Ascites, Decompensated Cirrhosis
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of ascites and complications in adult patients…
- Trial name
- NCT04112199
- Testing
- BIV201 continuous infusion
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- BioVie Inc.
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie